For instance, Kwon et al. [38] developed a series of small molecules that successfully inhibited the activity of complex III (ubiquinol-cytochrome c reductase binding protein, UQBP), which resulted in reducing tumour growth in preclinical xenograft models (harbouring U87MG glioblastoma cells) with no detectable in vitro or in vivo toxicity observed. The gene discussed is UQCRB; the disease is glioblastoma.